---
title: Samsung Biologics Launches CHF 1.46 Billion Tender Offer for PolyPeptide Group in Peptide CDMO Push
description: Samsung Biologics has launched a CHF 1.46 billion all-cash tender offer for PolyPeptide Group, expanding into GLP-1 and peptide therapeutics manufacturing.
author: Darie Nani (Editor-in-Chief)
date: 2026-07-20T08:49:06.778Z
updated: 2026-07-20T08:49:06.790Z
canonical: https://www.sovereignmagazine.com/article/samsung-biologics-polypeptide-chf-1-46-billion
image: https://cdn.nanimediahouse.com/desk-img-11.webp
categories: Science & Tech, Supply Chains
content_type: News
region: South Korea
publication: Sovereign Magazine
access: members
schema_type: Article
---

Samsung Biologics has announced an all-cash public tender offer to acquire 100% of PolyPeptide Group AG at CHF 44.31 per share, valuing the Swiss-listed peptide contract manufacturer at approximately CHF 1.46 billion and marking the South Korean biologics group's most significant strategic move into peptide and GLP-1 therapeutics manufacturing.

The offer represents a 40% premium to PolyPeptide's undisturbed share price of CHF 31.65, measured on 10 April 2026, the last trading day before market rumours of a deal emerged. PolyPeptide's board of directors, acting through its independent and non-conflicted members, has unanimously recommended acceptance. The company's largest shareholder, holding approximately 55.65% of outstanding shares, has provided an irrevocable tender undertaking, giving the transaction a firm majority foundation before the offer formally opens.

The deal is expected to launch at the end of August 2026 and complete by year-end, subject to a minimum 66⅔% acceptance threshold and the relevant regulatory approvals. Samsung Biologics intends to pursue a squeeze-out and delist PolyPeptide from the SIX Swiss Exchange following completion.

---

*This article is only available to registered readers. Visit the article URL to read the full piece.*